3.1 Base case
In this model AC is the dominant strategy with the ICRE of 6384.14
RMB/QALY. Using the base case probabilities and cost, AC cost is
105,453.73 RMB per patient which is 618.90 RMB fewer than NAC cost (with
106,072.63 per patients) in the initial treatment phase. And the average
QALY is 8.66 years for AC, and 8.56 for NAC.